Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Investment analysts at Wedbush upped their FY2018 earnings per share estimates for Ultragenyx Pharmaceutical in a note issued to investors on Tuesday, November 6th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings per share of ($3.95) for the year, up from their prior forecast of ($4.45). Wedbush currently has a “Outperform” rating and a $88.00 target price on the stock. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2018 earnings at ($1.78) EPS, Q1 2019 earnings at ($1.72) EPS, Q2 2019 earnings at ($1.71) EPS, Q3 2019 earnings at ($1.69) EPS, Q4 2019 earnings at ($1.66) EPS, FY2019 earnings at ($6.79) EPS, FY2020 earnings at ($5.31) EPS, FY2021 earnings at ($0.11) EPS and FY2022 earnings at $3.24 EPS.

A number of other equities analysts also recently commented on RARE. Raymond James upped their price objective on shares of Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, November 6th. Canaccord Genuity cut their price objective on shares of Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday. Citigroup upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $46.00 to $54.00 in a research report on Thursday. They noted that the move was a valuation call. ValuEngine downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. Finally, Piper Jaffray Companies cut their price objective on shares of Ultragenyx Pharmaceutical to $70.00 and set an “overweight” rating for the company in a research report on Friday, October 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $75.95.

Shares of Ultragenyx Pharmaceutical stock opened at $52.24 on Friday. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of -6.97 and a beta of 2.34. Ultragenyx Pharmaceutical has a one year low of $41.67 and a one year high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($1.74) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.94) by $0.20. The company had revenue of $11.80 million during the quarter, compared to the consensus estimate of $11.97 million. Ultragenyx Pharmaceutical had a negative net margin of 508.70% and a negative return on equity of 40.10%. Ultragenyx Pharmaceutical’s quarterly revenue was up 5800.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.87) EPS.

Institutional investors and hedge funds have recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $181,000. Janney Montgomery Scott LLC purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $313,000. JBF Capital Inc. purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $384,000. Strs Ohio increased its holdings in Ultragenyx Pharmaceutical by 358.3% during the 2nd quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 4,300 shares in the last quarter. Finally, Pier 88 Investment Partners LLC purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $446,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

In other news, EVP Karah Herdman Parschauer sold 5,000 shares of the stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $78.53, for a total value of $392,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Aliski sold 19,550 shares of the stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $72.49, for a total transaction of $1,417,179.50. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at approximately $5,263,498.90. The disclosure for this sale can be found here. Insiders sold a total of 37,250 shares of company stock valued at $2,747,319 in the last quarter. Insiders own 8.40% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Recommended Story: Why do companies engage in swaps?

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.